Aethlon Medical Secures $3.3 Million in Private Placement
Aethlon Medical, Inc. is taking a significant step forward in its mission to develop crucial medical therapies. The company has recently entered into a securities purchase agreement with a single institutional investor. This agreement allows for the purchase of approximately 595,897 shares of common stock, as well as additional warrants that could lead to the acquisition of up to 1,042,820 shares of common stock. The total gross proceeds from this private placement are estimated to be around $3.3 million.
Details of the Securities Purchase Agreement
The pricing for this offering is set at $4.03 per share, which aligns with the current market trends under Nasdaq regulations. Notably, Aethlon has also established a warrant inducement agreement that encourages the investor to act on certain outstanding warrants. This includes the March 2025 Warrants and September 2025 Warrants, which have been adjusted to an exercise price of $4.03. The investor is poised to exercise these warrants, contributing to an increase in shares effectively held.
Understanding the Investment Structure
Under this agreement, the investor is set to acquire an estimated 155,000 shares from the March 2025 Warrants and approximately 55,555 shares from the September 2025 Warrants, both at the new exercise price. In exchange for exercising these warrants immediately, Aethlon intends to issue additional unregistered warrants to purchase a further 368,471 shares of its common stock, ensuring that both parties benefit from this arrangement.
Anticipated Closure and Financial Projections
The entire offering is slated to close around December 8, 2025, pending standard requirements. As with any secure financial transaction, there will be standard fees associated with the placement. Maxim Group LLC is facilitating this offering as the sole placement agent, helping Aethlon navigate through the intricate landscape of private placements.
Future Perspectives for Aethlon Medical
This financial boost comes at a crucial time as Aethlon Medical is actively working on advancing their Hemopurifier technology. This innovative device is designed to tackle pressing healthcare challenges in oncology and infectious diseases. By efficiently removing harmful pathogenic targets from biological fluids, the Hemopurifier aims to fill critical gaps in the treatment landscape.
About Aethlon Medical, Inc.
Aethlon Medical, Inc., a clinical-stage medical device company, is dedicated to addressing unmet medical needs. With its headquarters located in a vibrant city known for innovation, the company focuses on revolutionary healthcare solutions. The Hemopurifier exemplifies Aethlon's commitment to improving patient outcomes through advanced medical technology, emphasizing its role in addressing significant medical challenges.
Future Developments and Expectations
Looking ahead, Aethlon Medical is preparing for a series of clinical trials that are critical for the validation of the Hemopurifier's efficacy. These trials, set to occur in various regions, aim to demonstrate the device's utility in real-world clinical settings, paving the way for future regulatory approvals and facilitating broader access to these groundbreaking treatments.
Frequently Asked Questions
What is the purpose of Aethlon's recent private placement?
Aethlon Medical's private placement aims to raise funds necessary for the development of its innovative therapies, particularly the Hemopurifier.
Who is the placement agent for this offering?
Maxim Group LLC is acting as the sole placement agent for Aethlon's recent securities offering.
What treatment does the Hemopurifier address?
The Hemopurifier focuses on treating cancer and life-threatening infectious diseases by removing harmful targets from the bloodstream.
When is the anticipated closing date for the offering?
The expected closing date for the offering is around December 8, 2025, subject to standard conditions being met.
How will the new funds impact Aethlon's operations?
The influx of new funds will allow Aethlon to accelerate its clinical trials and further the development of its Hemopurifier technology.
